Advertisement

Comparative Investigations of Terguride Isomers on Central Dopamine and Noradrenaline Functions

  • H. Wachtel
  • K.-J. Rettig
  • P.-A. Löschmann
  • G. Sauer
Part of the Advances in Behavioral Biology book series (ABBI, volume 39)

Abstract

Terguride is an 8α-ergoline derived from the dopamine (DA) receptor agonist lisuride. In previous neuropharmacological (Wachtel and Dorow, 1983) and neurobiochemical (Kehr, 1984) experiments terguride has been shown to exhibit a profile of action which characterises the compound as a DA partial agonist. Thus, at normosensitive central DA receptors the DA antagonistic component of action prevails (Wachtel and Dorow, 1983) whereas the DA agonistic component of action becomes evident at non-synaptic DA receptors like those located on pituitary lactotrophs (Wachtel and Dorow, 1983; Wachtel et al., 1984a) or is unmasked at supersensitive central DA receptors as judged from the release of contralateral rotations in rats bearing unilateral nigrostriatal lesions (Dlabac and Krejci, 1980), the production of stereotypies and hyperlocomotion in chronically reserpinised rats (Wachtel et al., 1984b) or the release of contralateral rotations in hemiparkinsonian 1methy-4-phenyl-1,2,3,6-tetrahydropyridine (MPTP)-treated monkeys (Brücke et al., 1988). The DA partial agonism of terguride might also contribute to reducing the incidence of unwanted side effects like nausea and emesis being associated with the use of DA agonists in man (Wachtel and Dorow, 1983).

Keywords

Stereotyped Behaviour Partial Agonistic Activity Automatic Registration Central Dopamine Contralateral Rotation 
These keywords were added by machine and not by the authors. This process is experimental and the keywords may be updated as the learning algorithm improves.

Preview

Unable to display preview. Download preview PDF.

Unable to display preview. Download preview PDF.

References

  1. Baumann, P.A. and Maitre, L., 1977, Blockade of presynaptic receptors and of amine uptake in the rat brain by the antidepressant mianserin, Naunyn-Schmiedeberg’s Arch. Pharmacol., 300: 31–37.CrossRefGoogle Scholar
  2. Brücke, T., Danielczyk, W., Simanyi, M., Sofic, E. and Riederer, P., 1986, Terguride: Partial dopamine agonist in the treatment of Parkinson’s disease, Adv. Neurol., 45: 573–576.Google Scholar
  3. Brücke, T., Bankiewicz, K., Harvey-White, J. and Kopin, I., 1988, The partial dopamine agonist terguride in the MPTP-induced hemiparkinsonian monkey model, Eur. J. Pharmacol., 148: 445–448.PubMedCrossRefGoogle Scholar
  4. Carlsson, A., 1983, Dopamine receptor agonists: Intrinsic activity vs. state of receptor, J. Neural Transm., 57: 309–315.PubMedCrossRefGoogle Scholar
  5. Ciccarelli, E., Touzel, R., Besser, M. and Grossman, A., 1988, Terguride–a new dopamine agonist drug: A comparison of its neuroendocrine and side effect profile with bromocriptine, Fertil. Steril., 49: 589–594.PubMedGoogle Scholar
  6. Corsini, G.U., Bonuccelli, U. Rainer, E. and del Zompo, M., 1985, Therapeutic efficacy of a partial dopamine agonist in drug-free Parkinsonian patients, J. Neural Transm., 64: 105–111.PubMedCrossRefGoogle Scholar
  7. Critchley, P. and Parkes, D., 1987, Transdihydrolisuride in parkinsonism, Clin. Neuropharmacol., 10: 57–64.PubMedCrossRefGoogle Scholar
  8. Crossley, D.I., 1984, The effects of idazoxan, an a2-adrenoceptor antagonist in depression - a preliminary investigation, Abstr. 9th IUPHAR Congress, London 1724 P.Google Scholar
  9. Dallabonzana, D., Liuzzi, A., Oppizzi, G., Cozzi, R., Verde, G., Chiodini, P., Rainer, E., Dorow, R. and Horowski, R., 1986, Chronic treatment of pathological hyperprolactinemia and acromegaly with the new ergot derivative terguride, J. Clin. Endocrinol. Metab., 63: 1002–1007.PubMedCrossRefGoogle Scholar
  10. Dlabac, A. and Krejci, I., 1980, Central dopaminergic effects of ergoline derivatives, Activ. Nerv. Sup., 22: 208–209.Google Scholar
  11. Filipovä, M., Filip, V., Mazek, Z., Müllerovä, J., Käs, S., Zizkovä, B., Krivka, J., Votava, M. and Krejcovä, H., 1988, Terguride in parkinsonism–a multicenter trial, Eur. Arch. Psychiat. Neurol. Sci., 237: 298–303.CrossRefGoogle Scholar
  12. Graf, K.-J., Köhler, D., Horowski, R. and Dorow, R, 1986, Rapid regression of macroprolactinomas by the new dopamine partial agonist terguride, Acta Endocrinol., 111: 460–466.PubMedGoogle Scholar
  13. Horowski, R., 1978, A new method for automatic registration of stereotyped behaviour in the rat, Arzneimittelforsch., 12: 2281–2286.Google Scholar
  14. Kehr, W., 1984, Transdihydrolisuride, a partial dopamine receptor antagonist: Effects on monoamine metabolism, Eur. J. Pharmacol., 97: 111–119.PubMedCrossRefGoogle Scholar
  15. Olbrich, R. and Schanz, H., 1988, The effect of the partial dopamine agonist terguride on negative symptoms in schizophrenics, Pharmacopsychiat., 21: 389–390.CrossRefGoogle Scholar
  16. Santamaria, J., Tolosa, E.S., Vallés, A., Bayes, A., Blesa, R. and Masana, J., 1986, Mental depression in untreated Parkinson’s disease of recent onset, Adv. Neurol., 45: 443–446.Google Scholar
  17. Sauer, G., Haffer, G. and Wachtel, H., 1986, Reduction of 8a-substituted 9,10-didehydroergolines, Synthesis, 12: 1007–1012.CrossRefGoogle Scholar
  18. Suchy, I., Rinne, U.K. and Wachtel, H., 1986, Evaluation of terguride in patients with Parkinson’s disease, Adv. Neurol., 45: 577–581.Google Scholar
  19. Timsit, J., 1967, Activité cataleptigène de quelques neuroleptiques et quelques parasympathomiméthiques chez la souris, Therapie, 22: 885–893.PubMedGoogle Scholar
  20. Venturini, P.L., Horowski, R., Fasce, V., Valenzano, M., Ferreri, C., Badino, G., Rainer, E., Scholz, A. and de Cecco, L., 1988, Suppression of puerperal lactaton by terguride: A double-blind study, Gynecol. Obstet. Invest., 26: 33–38.PubMedCrossRefGoogle Scholar
  21. Wachtel, H. and Dorow, R., 1983, Dual action on central dopamine function of transdihydrolisuride, a 9,10-dihydrogenated analogue of the ergot dopamine agonist lisuride, Life Sci., 32: 421–432.PubMedCrossRefGoogle Scholar
  22. Wachtel, H., Dorow, R. and Sauer, G., 1984a, Novel 8a-ergolines with inhibitory and stimulatory effects on prolactin secretion in rats, Life Sci., 35: 1859–1867.PubMedCrossRefGoogle Scholar
  23. Wachtel, H., Rettig, K.-J. and Seltz, A., 1984b, The central dopamine agonistic action of transdihydrolisuride is unmasked at supersensitive receptors, Naunyn-Schmiedeberg’s Arch. Pharmacol., 325 (Suppl.): R80.CrossRefGoogle Scholar

Copyright information

© Plenum Press, New York 1991

Authors and Affiliations

  • H. Wachtel
    • 1
  • K.-J. Rettig
    • 1
  • P.-A. Löschmann
    • 1
  • G. Sauer
    • 1
  1. 1.Research Laboratories of Schering AGBerlin and BergkamenGermany

Personalised recommendations